U.S. Markets closed
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • Dow 30

    34,429.88
    +34.87 (+0.10%)
     
  • Nasdaq

    11,461.50
    -20.95 (-0.18%)
     
  • Russell 2000

    1,892.84
    +11.16 (+0.59%)
     
  • Crude Oil

    80.34
    -0.88 (-1.08%)
     
  • Gold

    1,811.40
    -3.80 (-0.21%)
     
  • Silver

    23.35
    +0.51 (+2.25%)
     
  • EUR/USD

    1.0531
    +0.0002 (+0.0211%)
     
  • 10-Yr Bond

    3.5060
    -0.0230 (-0.65%)
     
  • Vix

    19.06
    -0.78 (-3.93%)
     
  • GBP/USD

    1.2296
    +0.0040 (+0.3258%)
     
  • USD/JPY

    134.2710
    -1.0350 (-0.7649%)
     
  • BTC-USD

    16,977.04
    +12.95 (+0.08%)
     
  • CMC Crypto 200

    404.33
    +2.91 (+0.72%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Analyst: Centogene Leveraging The Largest BioDatabank For Rare Diseases

  • HC Wainwright initiated coverage on Germany-based Centogene NV (NASDAQ: CNTG) with a Buy rating and a price target of $2.50.

  • Centogene is a diagnostics company. According to management, Centogene offers the broadest diagnostic testing portfolio for rare diseases, covering over 19,000 genes using over 10,000 different tests.

  • The analyst notes that the company intends to strengthen its position in rare diseases by continuing to build its BioDatabank as the world's most comprehensive repository of rare disease patient data.

  • Centogene aims to fully execute it's existing over 20 ongoing partnerships and target approximately 20 new pipeline deals. In addition, the company may establish and pursue its discovery programs or co-invest in partnered programs.

  • The company's core revenue (Diagnostics and Pharma) was €43.5 million in 2021. Management has guided that 2022 revenue would be €50-52 million with a growth rate of 15-20% Y/Y.

  • In 2021, the company's COVID-19 testing sales reached €146.4 million, falling to €19.5 million in 1Q22.

  • Due to declining demand, the company discontinued the COVID-19 business at the end of March 2022, generating significant pressure on the share price.

  • The analyst says that the management made a sound decision to focus on the core business that provides substantial growth opportunities, citing the continued decline in COVID-19 testing.

  • The current share price represents an attractive entry point.

  • Price Action: CNTG shares are up 6.40% at $0.80 on the last check Wednesday.

Latest Ratings for CNTG

Date

Firm

Action

From

To

Jun 2021

Credit Suisse

Maintains

Outperform

Nov 2020

Credit Suisse

Initiates Coverage On

Outperform

Oct 2020

Kempen & Co

Initiates Coverage On

Buy

View More Analyst Ratings for CNTG

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.